Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;76(5):796-805.
doi: 10.1002/art.42785. Epub 2024 Feb 6.

Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease

Atsuki Fukada  1 , Tomoyuki Fujisawa  1 , Hironao Hozumi  1 , Keigo Koda  2 , Taisuke Akamatsu  3 , Yoshiyuki Oyama  4 , Yasuomi Satake  5 , Mitsuru Niwa  6 , Yusuke Kaida  7 , Hiroyuki Matsuda  8 , Koshi Yokomura  9 , Naoki Koshimizu  10 , Mikio Toyoshima  2 , Shiro Imokawa  11 , Dai Hashimoto  12 , Akira Yoshida  13 , Takahisa Gono  13 , Masataka Kuwana  13 , Yasuhiko Yamano  14 , Yasuhiro Kondoh  14 , Keita Yamashita  1 , Masato Maekawa  1 , Kazutaka Mori  15 , Yusuke Inoue  1 , Hideki Yasui  1 , Yuzo Suzuki  1 , Masato Karayama  1 , Kazuki Furuhashi  1 , Noriyuki Enomoto  1 , Naoki Inui  1 , Takafumi Suda  1
Affiliations

Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease

Atsuki Fukada et al. Arthritis Rheumatol. 2024 May.

Abstract

Objective: Interferon-λ3 (IFNλ3) is a cytokine with antiviral functions on barrier surfaces, and it is associated with disease activity in autoimmune diseases. This study assessed the clinical significance of serum IFNλ3 levels in polymyositis/dermatomyositis (PM/DM)-associated interstitial lung disease (ILD).

Methods: We measured serum IFNλ3 levels in 221 patients with PM/DM-ILD (155 in the derivation cohort, 66 in the validation cohort) and 38 controls. We evaluated factors associated with mortality risk among 79 patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive DM-ILD.

Results: Serum IFNλ3 levels at diagnosis were significantly higher in patients with PM/DM-ILD than in healthy controls. Remarkably, serum IFNλ3 levels were specifically increased in patients with anti-MDA5 antibody-positive DM-ILD in both the derivation and validation cohorts. In anti-MDA5 antibody-positive DM-ILD, patients with high IFNλ3 levels (>120 pg/mL) had significantly lower survival rates than those with low IFNλ3 levels (≤120 pg/mL). A multivariate analysis revealed that high IFNλ3 levels, as well as old age and low Pao2, were significantly associated with poor prognoses in patients with anti-MDA5 antibody-positive DM-ILD. In a classification analysis of patients with anti-MDA5 antibody-positive DM-ILD based on age, IFNλ3 level, and Pao2, patients with old age (>53 years), high IFNλ3 levels (>120 pg/mL), and low Pao2 (<75 mm Hg) had the worst survival. In lung pathologic analyses, IFNλ3-positive staining was observed in macrophages, airway epithelial cells, the pleural region, and intrapulmonary veins in patients with anti-MDA5 antibody-positive DM-ILD.

Conclusion: Serum IFNλ3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody-positive DM-ILD.

PubMed Disclaimer

References

REFERENCES

    1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292(7):344–347.
    1. Lundberg IE, Tjärnlund A, Bottai M, et al; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017;69(12):2271–2282.
    1. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005;32(1):58–64.
    1. Marie I, Hatron PY, Dominique S, et al. Short‐term and long‐term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011;63(11):3439–3447.
    1. Fujisawa T, Hozumi H, Kono M, et al. Prognostic factors for myositis‐associated interstitial lung disease. PLoS One 2014;9(6):e98824.

Publication types

LinkOut - more resources